Clinical Edge Journal Scan

Rural AML patients fare as well as urban patients for survival and treatment


 

Key clinical point: No significant differences were seen between urban and rural acute myeloid leukemia patients with regard to overall survival or progression to hematopoietic cell transplantation.

Major finding: Overall survival at one year was 47.9% between the groups (45% for rural and 49% for urban). In addition, the proportions of patients with cytogenetic risk factors and who went on to hematopoietic cell transplantation (HCT) were not significantly different between the two groups.

Study details: The data come from a retrospective study of 163 acute myeloid leukemia patients diagnosed at a single center between September 2015 and December 2019, 42% of whom lived in a rural area at the time of diagnosis.

Disclosures: The study received no outside funding. Lead author Dr. Isaac had no financial conflicts to disclose.

Source: Isaac KM et al. Cancer Rep 2021 Mar 9. doi: 10.1002/cnr2.1354.

Recommended Reading

Beat AML: Precision medicine strategy feasible, superior to SOC for AML
MDedge Hematology and Oncology
Prevention of HMA failure a goal for high-risk MDS posttransplant
MDedge Hematology and Oncology
Black race linked to poorer survival in AML
MDedge Hematology and Oncology
Chronic GVHD therapies offer hope for treating refractory disease
MDedge Hematology and Oncology
Transplant-related mortality higher with CD34 selection
MDedge Hematology and Oncology
Using engineered T cells reduced acute, chronic GVHD
MDedge Hematology and Oncology
Maribavir seen as superior to other antivirals for CMV clearance post transplant
MDedge Hematology and Oncology
Don’t delay: Cancer patients need both doses of COVID vaccine
MDedge Hematology and Oncology
Omidubicel improves on umbilical cord blood transplants
MDedge Hematology and Oncology
Risk factors predict graft failure in pediatric acute leukemia patients
MDedge Hematology and Oncology